Physiologically Based Pharmacokinetic Modeling in Neonates: Current Status and Future Perspectives

Area of Science:

• Pharmacology
• Pediatrics
• Computational Biology

Background:

• Neonates exhibit unique physiological differences impacting drug absorption, distribution, metabolism, and excretion.
• Accurate drug dosing in neonates is critical to ensure therapeutic efficacy and prevent toxicity.
• Traditional clinical trials in neonates are challenging due to ethical and practical considerations.

Purpose of the Study:

• To review age-dependent physiological factors influencing neonatal pharmacokinetics.
• To explore the application of physiologically based pharmacokinetic (PBPK) modeling in neonatal drug development.
• To discuss future perspectives for PBPK modeling in neonatal care.

Main Methods:

• Literature review of studies on neonatal physiological changes affecting drug disposition.
• Analysis of PBPK modeling applications in pediatric pharmacology.
• Synthesis of current research on PBPK model verification and utility.

Main Results:

• PBPK models can predict drug plasma concentrations in newborns, compensating for clinical trial limitations.
• These models provide valuable insights for designing neonatal clinical research.
• PBPK modeling has been successfully applied to various medications in neonatal studies.

Conclusions:

• PBPK modeling is a powerful tool for optimizing drug therapy in neonates.
• Further development and application of PBPK models are crucial for advancing neonatal pharmacotherapy.
• This approach enhances rational drug use in this vulnerable population.